Julio Escribano

Prof. Julio Escribano

University of Castilla-La Mancha, Ciudad Real, Spain
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2006 in Nature Neuroscience
Verified
Journal Article
Closed access
Carmen RamírezCarmen Ramírez
Carmen Ramírez
FSFrancisco Sánchez-Sánchez
Francisco Sánchez-Sánchez
CACelia Andreu-Agulló
Celia Andreu-Agulló
SFSacri R Ferrón
Sacri R Ferrón
Jose Daniel Aroca-AguilarJose Daniel Aroca-Aguilar
Jose Daniel Aroca-Aguilar
IFIsabel Fariñas
Isabel Fariñas

1 February 1996 in Cancer Letters
Verified
Journal Article
Open access
Julio EscribanoJulio Escribano
Julio Escribano
GAGonzalo L. Alonso
Gonzalo L. Alonso
MCMiguel Coca-Prados
Miguel Coca-Prados
JFJosé-Antonio Fernández
José-Antonio Fernández
Extracts of saffron (Crocus sativus L.) have been reported to inhibit cell growth of human tumor cells. In order to study the cytotoxic effect of the characteristic compounds of saffron spice, we have isolated crocin, crocetin, picrocrocin and safranal. Doses inducing 50% cell growth inhibition (LD50) on HeLa cells were 2.3 mg/ml for an ethanolic extract of saffron dry stigmas, 3 mM for crocin, 0.8 mM for safranal and 3 mM for picrocrocin. Crocetin did not show cytotoxic effect. Cells treated with crocin exhibited wide cytoplasmic vacuole-like areas, reduced cytoplasm, cell shrinkage and pyknotic nuclei, suggesting apoptosis induction. Considering its water-solubility and high inhibitory growth effect, crocin is the more promising saffron compound to be assayed as a cancer therapeutic agent.

1 December 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
LNLuigi Notari
Luigi Notari
Victoriano BaladrónVictoriano Baladrón
Victoriano Baladrón
Jose Daniel Aroca-AguilarJose Daniel Aroca-Aguilar
Jose Daniel Aroca-Aguilar
NBNatalia Balko
Natalia Balko
RHRaul Heredia
Raul Heredia
SBS.PAtricia Becerra
S.PAtricia Becerra
Pigment epithelium-derived factor (PEDF) is an extracellular multifunctional protein belonging to the serpin superfamily with demonstrable neurotrophic, gliastatic, neuronotrophic, antiangiogenic, and antitumorigenic properties. We have previously provided biochemical evidence for high affinity PEDF-binding sites and proteins in plasma membranes of retina, retinoblastoma, and CNS cells. This study was designed to reveal a receptor involved in the biological activities of PEDF. Using a yeast two-hybrid screening, we identified a novel gene from pigment epithelium of the human retina that codes for a PEDF-binding partner, which we term PEDF-R. The derived polypeptide has putative transmembrane, intracellular and extracellular regions, and a phospholipase domain. Recently, PEDF-R (TTS-2.2/independent phospholipase A(2) (PLA(2))zeta and mouse desnutrin/ATGL) has been described in adipose cells as a member of the new calcium-independent PLA(2)/nutrin/patatin-like phospholipase domain-containing 2 (PNPLA2) family that possesses triglyceride lipase and acylglycerol transacylase activities. Here we describe the PEDF-R gene expression in the retina and its heterologous expression by bacterial and eukaryotic systems, and we demonstrate that its protein product has specific and high binding affinity for PEDF, has a potent phospholipase A(2) activity that liberates fatty acids, and is associated with eukaryotic cell membranes. Most importantly, PEDF binding stimulates the enzymatic phospholipase A(2) activity of PEDF-R. In conclusion, we have identified a novel PEDF-R gene in the retina for a phospholipase-linked membrane protein with high affinity for PEDF, suggesting a molecular pathway by which ligand/receptor interaction on the cell surface could generate a cellular signal.



1 November 1999 in Nutrition and Cancer
Verified
Journal Article
Closed access
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
HRHans H. Riese
Hans H. Riese
Julio EscribanoJulio Escribano
Julio Escribano
JOJesús Onta˜´n
Jesús Onta˜´n
JFJosé A Fernandez
José A Fernandez
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
We used an experimental model in the rat to exam-ine the effects of long-term treatment with crocin, a glyco-sylated carotenoid from the stigmas of the saffron crocus, on colon cancer. BD-IX rats were divided into four groups: Groups G1 and G2, designated "cancer groups," were used to study the effects of crocin on the progression of colon can-cer, and Groups G3 and G4, designated "toxicity groups," were used to study the effects of the treatment on metabolic processes and the parenchyma. DHD/K12-PROb cells were injected subcutaneously into the chest of Group G1 and G2 animals. From 1 to 13 weeks after inoculation, animals in Groups G2 and G4 received a weekly injection of crocin (400 mg/kg body wt sc). Animals in Groups G1 and G3 re-ceived no treatment. In addition, lines of animal and human colon adenocarcinoma cells (DHD/K12-PROb and HT-29) were used to perform assays in vitro to examine the cyto-toxicity of crocin. Life span was extended and tumor growth was slower in crocin-treated female rats, but n...